We are live on
!
Find out more
LCM
Laurion Capital Management Portfolio holdings
AUM
$2.29B
1-Year Est. Return
75.73%
This Fund
S&P 500
This Quarter
Est. Return
+6.97%
1 Year Est. Return
+75.73%
3 Year Est. Return
+162.63%
5 Year Est. Return
+130.38%
10 Year Est. Return
+388.8%
AUM
$17.9B
AUM Growth
+$3.18B
(+22%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.82%
Top 10 Holdings %
Top 10 Hldgs %
38.29%
Holding
721
New
293
Increased
98
Reduced
124
Closed
140
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$124M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$95.2M |
| 3 |
Pliant Therapeutics
PLRX
|
+$74.8M |
| 4 |
Microsoft
MSFT
|
+$72.6M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$56.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$123M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$60.4M |
| 3 |
Emerson Electric
EMR
|
+$55M |
| 4 |
Home Depot
HD
|
+$54.8M |
| 5 |
Comcast
CMCSA
|
+$53.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 5.44% |
| 2 | Technology | 2.51% |
| 3 | Communication Services | 1.69% |
| 4 | Utilities | 1.38% |
| 5 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OMGA
501
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $135K | ﹤0.01% |
24,155
-546,953
| -96% | -$4.28M |
|
502
LSB Industries
LXU
$693M
| $134K | ﹤0.01% |
+13,555
| New | +$130K |
|
|
BIG
503
DELISTED
Big Lots, Inc.
BIG
| $131K | ﹤0.01% |
+14,842
| New | +$126K |
|
504
Tredegar Corp
TG
$310M
| $126K | ﹤0.01% |
+18,885
| New | +$150K |
|
|
AMPS
505
DELISTED
Altus Power
AMPS
| $122K | ﹤0.01% |
+22,628
| New | +$112K |
|
|
DAWN
506
DELISTED
Day One Biopharmaceuticals
DAWN
| $121K | ﹤0.01% |
10,134
-4,866
| -32% | -$63.6K |
|
507
Identive
INVE
$61.9M
| $117K | ﹤0.01% |
+13,921
| New | +$95K |
|
508
Douglas Elliman
DOUG
$162M
| $115K | ﹤0.01% |
+52,009
| New | +$143K |
|
509
Oportun Financial
OPRT
$372M
| $115K | ﹤0.01% |
+19,328
| New | +$94.9K |
|
510
Alto Ingredients
ALTO
$340M
| $115K | ﹤0.01% |
+39,630
| New | +$75.5K |
|
511
PUT
Verisk Analytics
VRSK
$25B
| $113K | ﹤0.01% |
+500
| New | +$105K |
|
|
SQZ
512
DELISTED
SQZ Biotechnologies Company
SQZ
| $111K | ﹤0.01% |
412,865
-18,535
| -4% | -$10.5K |
|
513
Fulcrum Therapeutics
FULC
$297M
| $111K | ﹤0.01% |
+33,645
| New | +$98.9K |
|
|
IONQ.WS
514
IonQ Inc Warrants
IONQ.WS
$8.06B
| $110K | ﹤0.01% |
25,000
| – | – |
|
|
FIRY
515
Firy Inc
FIRY
$163M
| $107K | ﹤0.01% |
+11,810
| New | +$137K |
|
|
LTCH
516
DELISTED
Latch, Inc. Common Stock
LTCH
| $107K | ﹤0.01% |
+77,100
| New | +$72K |
|
|
ILPT
517
Industrial Logistics Properties Trust
ILPT
$586M
| $103K | ﹤0.01% |
31,187
+15,581
| +100% | +$34.8K |
|
518
Karyopharm Therapeutics
KPTI
$48M
| $102K | ﹤0.01% |
+3,810
| New | +$164K |
|
519
Uranium Energy
UEC
$5.57B
| $101K | ﹤0.01% |
+29,606
| New | +$84.5K |
|
|
AMTI
520
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $99.9K | ﹤0.01% |
387,383
-94,217
| -20% | -$26.7K |
|
521
AXT Inc
AXTI
$5.8B
| $97.3K | ﹤0.01% |
+28,273
| New | +$95.3K |
|
|
FSP
522
Franklin Street Properties
FSP
$46.8M
| $93.4K | ﹤0.01% |
64,401
+43,464
| +208% | +$60.1K |
|
523
Goldman Sachs
GS
$303B
| $92.6K | ﹤0.01% |
287
-359
| -56% | -$118K |
|
|
524
Comcast
CMCSA
$90B
| $92.4K | ﹤0.01% |
2,223
-1,357,534
| -100% | -$53.9M |
|
525
The RealReal
REAL
$1.5B
| $92.1K | ﹤0.01% |
+41,498
| New | +$56.8K |
|
Similar funds
AFM
GCP
LCM
MAP
MA
LFM
NSAM
ABI
Laurion Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Laurion Capital Management held 721 positions worth $17.9B, up 22% from $14.7B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Laurion Capital Management deployed $2.11B of net new capital in Q2 2023, opening 293 new positions and adding to 98 existing holdings. Its largest new stake was Pliant Therapeutics: 3,158,570 shares worth $57.2M.
By sector, the portfolio is most concentrated in Healthcare at 5.4% of assets, down from 6.6% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Viatris, an estimated $123M trimmed.
- Laurion Capital Management's largest Q2 2023 buy was Pliant Therapeutics: 3,158,570 shares worth $57.2M.
- Laurion Capital Management added most to T-Mobile US in Q2 2023, an estimated $124M increase.
- Laurion Capital Management's biggest Q2 2023 reduction was Viatris, cutting an estimated $123M.
- Laurion Capital Management fully exited CATALENT, INC. in Q2 2023, selling an estimated $60.4M.
- Laurion Capital Management's ten largest holdings make up 38% of its $17.9B portfolio in Q2 2023.
- Laurion Capital Management opened 293 new positions and closed 140 in Q2 2023.
- Laurion Capital Management's portfolio value rose 22% quarter-over-quarter to $17.9B.
Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.